Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
IMRX Stock Summary
Top 10 Correlated ETFs
IMRX
In the News
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024.
Immuneering (IMRX) Plummets 71% in One Week: Here's Why
Immuneering (IMRX) plunges after multiple Wall Street analysts downgraded the stock on lackluster results from an early-stage study evaluating its lead drug across advanced RAS-mutant solid tumors.
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, announced today that it will be presenting preclinical data on its lead program IMM-1-104 at the American Association for Cancer Research (AACR) annual meeting, held April 5-10 in San Diego, California.
Immuneering Announces Participation in February Investor Conferences
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in two February investor conferences to discuss the company's pipeline, platform and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the 35th Annual Piper Sandler Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Brett Hall, Ph.D., Chief Scientific Officer, Harold “E.B.” Brakewood, Chief Business Officer, and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it will present preclinical data on IMM-1-104, its lead clinical-stage program, and IMM-6-415 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15, 2023 in Boston.
Immuneering to Present at the Morgan Stanley Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Morgan Stanley Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Chief Accounting Officer and Treasurer.
Immuneering Corp.: Early Stage Promise, But Long-Term Investment
IMRX is an early-stage company with promising science. They do not have clinical efficacy data. While I like the company, be warned that this is going to take time.
Wall Street Analysts Think Immuneering Corporation (IMRX) Could Surge 103.8%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 103.8% in Immuneering Corporation (IMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Immuneering to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that management will present at the Jefferies Healthcare Conference to discuss the company's pipeline, platform, and business strategy. Participating will be Ben Zeskind, Ph.D., Co-Founder and Chief Executive Officer, Scott Barrett, M.D., Chief Medical Officer, Brett Hall, Ph.D., Chief Scientific Officer, and Mallory Morales, CPA, Vice President of Finance, Treasurer.
IMRX Financial details
IMRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.22 | 0.17 | 0.15 | 0.01 | 0 | |
Net income per share | -0.94 | -1.26 | -2.46 | -1.87 | -1.88 | |
Operating cash flow per share | -0.52 | -1.08 | -2.27 | -1.67 | -1.72 | |
Free cash flow per share | -0.52 | -1.09 | -2.27 | -1.7 | -1.74 | |
Cash per share | 1.61 | 2.75 | 10.96 | 4 | 3.01 | |
Book value per share | -0.76 | -1.66 | 11.46 | 4.16 | 3.19 | |
Tangible book value per share | -0.76 | -1.66 | 10.93 | 3.89 | 2.94 | |
Share holders equity per share | -0.76 | -1.66 | 11.46 | 4.16 | 3.19 | |
Interest debt per share | 1.98 | 0.05 | 0.39 | 0.22 | 0.16 | |
Market cap | 150.9M | 237.67M | 220.12M | 127.98M | 208.86M | |
Enterprise value | 153.73M | 201.2M | 150.59M | 60.18M | 153.92M | |
P/E ratio | -18.72 | -13.95 | -6.56 | -2.6 | -3.91 | |
Price to sales ratio | 78.61 | 102.82 | 105.83 | 403.77 | 0 | |
POCF ratio | -33.97 | -16.26 | -7.13 | -2.9 | -4.27 | |
PFCF ratio | -33.81 | -16.2 | -7.12 | -2.85 | -4.24 | |
P/B Ratio | -23.12 | -10.57 | 1.41 | 1.17 | 2.31 | |
PTB ratio | -23.12 | -10.57 | 1.41 | 1.17 | 2.31 | |
EV to sales | 80.08 | 87.04 | 72.4 | 189.87 | 0 | |
Enterprise value over EBITDA | -20.94 | -11.86 | -4.44 | -1.16 | -2.67 | |
EV to operating cash flow | -34.61 | -13.76 | -4.88 | -1.36 | -3.14 | |
EV to free cash flow | -34.45 | -13.71 | -4.87 | -1.34 | -3.12 | |
Earnings yield | -0.05 | -0.07 | -0.15 | -0.39 | -0.26 | |
Free cash flow yield | -0.03 | -0.06 | -0.14 | -0.35 | -0.24 | |
Debt to equity | -2.55 | -0.03 | 0.03 | 0.04 | 0.05 | |
Debt to assets | 1.18 | 0.02 | 0.03 | 0.04 | 0.04 | |
Net debt to EBITDA | -0.39 | 2.15 | 2.05 | 1.31 | 0.95 | |
Current ratio | 27.83 | 16.73 | 27.04 | 13.5 | 11.35 | |
Interest coverage | -17.91 | 0 | 0 | -51.01 | 0 | |
Income quality | 0.58 | 0.86 | 0.92 | 0.87 | 0.92 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 1.41 | 1.35 | 3.98 | 49.24 | 0 | |
Research and developement to revenue | 2.23 | 6.49 | 12.76 | 114.42 | 0 | |
Intangibles to total assets | 0 | 0 | 0.04 | 0.06 | 0.07 | |
Capex to operating cash flow | 0 | 0 | 0 | 0.02 | 0.01 | |
Capex to revenue | -0.01 | -0.02 | -0.03 | -2.34 | 0 | |
Capex to depreciation | -1.14 | -0.67 | -0.38 | -0.93 | -0.97 | |
Stock based compensation to revenue | 0.31 | 0.47 | 0.87 | 12.82 | 0 | |
Graham number | 4.01 | 6.87 | 25.2 | 13.23 | 11.62 | |
ROIC | -0.65 | 0.8 | -0.2 | -0.42 | -0.59 | |
Return on tangible assets | -0.57 | -0.44 | -0.21 | -0.43 | -0.56 | |
Graham Net | -0.78 | -1.73 | 10.19 | 3.53 | 2.59 | |
Working capital | 13.56M | 35.48M | 146.7M | 100.69M | 81.24M | |
Tangible asset value | -6.53M | -22.48M | 148.84M | 102.75M | 83.51M | |
Net current asset value | -6.56M | -23.17M | 141.61M | 96.23M | 77.08M | |
Invested capital | -2.55 | -0.03 | 0.03 | 0.04 | 0.05 | |
Average receivables | 0 | 355.03K | 373.08K | 129.23K | 6.21K | |
Average payables | 0 | 887.74K | 1.44M | 2.27M | 2.63M | |
Average inventory | 0 | 0 | 0 | 0.5 | 0.5 | |
Days sales outstanding | 39.92 | 78.97 | 43.18 | 14.3 | 0 | |
Days payables outstanding | 88.03 | 422.08 | 441.37 | 7.28K | 1.01K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 9.14 | 4.62 | 8.45 | 25.53 | 0 | |
Payables turnover | 4.15 | 0.86 | 0.83 | 0.05 | 0.36 | |
Inventory turnover | 0 | 0 | 0 | 158.12K | 0 | |
ROE | 1.24 | 0.76 | -0.22 | -0.45 | -0.59 | |
Capex per share | 0 | 0 | 0 | -0.03 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 3.3 | 0 | 0 | |
Net income per share | -0.47 | 40.16 | -0.43 | -0.43 | -0.52 | |
Operating cash flow per share | -0.44 | -0.55 | -0.38 | -0.41 | -0.4 | |
Free cash flow per share | -0.45 | -0.55 | -0.38 | -0.41 | -0.41 | |
Cash per share | 4 | 3.46 | 3.8 | 3.32 | 2.93 | |
Book value per share | 4.16 | 3.7 | 4.02 | 3.55 | 3.09 | |
Tangible book value per share | 3.89 | 3.43 | 3.77 | 3.31 | 2.85 | |
Share holders equity per share | 4.16 | 3.7 | 4.02 | 3.55 | 3.09 | |
Interest debt per share | 0.2 | -40.49 | 0.16 | 0.16 | 0.15 | |
Market cap | 128.07M | 256.75M | 290.49M | 224.77M | 215.13M | |
Enterprise value | 60.28M | 184.07M | 191.11M | 161.27M | 160.19M | |
P/E ratio | -2.56 | 0.06 | -5.96 | -4.46 | -3.57 | |
Price to sales ratio | 280.86K | 0 | 3.08 | 0 | 0 | |
POCF ratio | -10.9 | -17.81 | -27.03 | -18.69 | -18.27 | |
PFCF ratio | -10.84 | -17.77 | -26.81 | -18.6 | -18.01 | |
P/B Ratio | 1.17 | 2.63 | 2.52 | 2.16 | 2.38 | |
PTB ratio | 1.17 | 2.63 | 2.52 | 2.16 | 2.38 | |
EV to sales | 132.19K | 0 | 2.02 | 0 | 0 | |
Enterprise value over EBITDA | -4.31 | -12.7 | -14.16 | -0.01 | -9.88 | |
EV to operating cash flow | -5.13 | -12.77 | -17.78 | -13.41 | -13.6 | |
EV to free cash flow | -5.1 | -12.74 | -17.64 | -13.35 | -13.41 | |
Earnings yield | -0.1 | 4.14 | -0.04 | -0.06 | -0.07 | |
Free cash flow yield | -0.09 | -0.06 | -0.04 | -0.05 | -0.06 | |
Debt to equity | 0.04 | 0.05 | 0.04 | 0.04 | 0.05 | |
Debt to assets | 0.04 | 0.04 | 0.04 | 0.04 | 0.04 | |
Net debt to EBITDA | 4.85 | 5.02 | 7.36 | 0 | 3.39 | |
Current ratio | 13.5 | 17.05 | 20.35 | 17.89 | 11.35 | |
Interest coverage | -27.09 | 0.01 | 0 | 0 | 0 | |
Income quality | 0.89 | 1.06 | 0.88 | 0.95 | 0.78 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 9.01K | 0 | 0.04 | 0 | 0 | |
Research and developement to revenue | 21.65K | 0 | 0.1 | 0 | 0 | |
Intangibles to total assets | 0.06 | 0.07 | 0.06 | 0.06 | 0.07 | |
Capex to operating cash flow | 0.01 | 0 | 0.01 | 0 | 0.01 | |
Capex to revenue | -151.98 | 0 | 0 | 0 | 0 | |
Capex to depreciation | -0.37 | -0.15 | 4.29 | -0.67 | -1.76 | |
Stock based compensation to revenue | 2.3K | 0 | 0.01 | 0 | 0 | |
Graham number | 6.66 | 57.8 | 6.2 | 5.87 | 5.99 | |
ROIC | -0.11 | 10.68 | -0.1 | -0.12 | -0.16 | |
Return on tangible assets | -0.11 | 10.55 | -0.1 | -0.12 | -0.16 | |
Graham Net | 3.52 | 3.09 | 3.46 | 2.99 | 2.52 | |
Working capital | 100.69M | 88.71M | 106.03M | 94.96M | 81.24M | |
Tangible asset value | 102.75M | 90.7M | 108.02M | 96.94M | 83.51M | |
Net current asset value | 96.23M | 84.33M | 101.72M | 90.72M | 77.08M | |
Invested capital | 0.04 | 0.05 | 0.04 | 0.04 | 0.05 | |
Average receivables | 41.3K | 6.73K | 523 | 0 | 0 | |
Average payables | 2.75M | 2.94M | 2.71M | 2.32M | 2.03M | |
Average inventory | 0.5 | 0.5 | 0 | 0 | 0 | |
Days sales outstanding | 2.45K | 0 | 0 | 0 | 0 | |
Days payables outstanding | 1.8 | 1.29K | 1.25K | 892.3 | 1.03K | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0.04 | 0 | 0 | 0 | 0 | |
Payables turnover | 50.07 | 0.07 | 0.07 | 0.1 | 0.09 | |
Inventory turnover | 157.96M | 0 | 0 | 0 | 0 | |
ROE | -0.11 | 10.86 | -0.11 | -0.12 | -0.17 | |
Capex per share | 0 | 0 | 0 | 0 | -0.01 |
IMRX Frequently Asked Questions
What is Immuneering Corporation stock symbol ?
Immuneering Corporation is a US stock , located in Cambridge of Ma and trading under the symbol IMRX
Is Immuneering Corporation buy or a sell ?
3 stock analysts have 3 predictions with a medium analyst target price of $20.67. The lowest prediction is $3 and the highest is $41
What is IMRX stock prediction ?
With a median analyst target price of $3, 1 stock analysts have made 1 forecasts in last 90 days. $3 is the lowest and $3 is the greatest projection.
What is Immuneering Corporation stock quote today ?
Immuneering Corporation stock price is $2.43 today.
Is Immuneering Corporation stock public?
Yes, Immuneering Corporation is a publicly traded company.